Reverse pseudohyperkalemia is a term used to describe in vitro, falsely elevated potassium concentrations in plasma specimens that occur in association with extreme leukocytosis and are commonly associated with hematologic malignant neoplasms. Tumor lysis syndrome is an in vivo lysis of tumor cells that leads to elevated levels of potassium, uric acid, phosphate, and lactate dehydrogenase, as well as decreased calcium concentrations. Herein, we report a case of a 66-year-old Caucasian man with stage IV mantle-cell lymphoma who has elevated levels of potassium, uric acid, and phosphorus, as well as a white blood cell (WBC) count greater than 100,000 cells per mm 3 . The patient initially was diagnosed as having tumor lysis syndrome. His subsequent potassium concentrations in whole blood remained elevated even after hemodialysis; however, his serum potassium concentrations were decreased. The patient then was diagnosed accurately as having reverse pseudohyperkalemia, and accurate potassium measurements were obtained via serum specimens.
), uric acid level of 13.5 mg per dL (reference range, 2.4 to 7.0 mg/dL), and calcium concentration of 8.1 mg per dL (reference range, 8.5 to 10.3 mg/dL). Potassium concentration was not reported because the plasma specimen was moderately hemolyzed. The patient had a past medical history of mantle-cell lymphoma, antineutrophil cytoplasmic antibody (ANCA)-positive vasculitis, and nephritis, with creatinine baseline at approximately 3.0 mg per dL, along with hypertension and atrial fibrillation. One year and 7 months prior, he was diagnosed with stage IV mantle-cell lymphoma and was treated with bendamustine and rituximab; for the past 8 months, he had undergone rituximab maintenance therapy. However, his lymphoma relapsed, and the patient developed progressive dyspnea, intrathoracic lymphadenopathy, and leukocytosis. Flow cytometric studies identified mantle-cell lymphoma cells in his peripheral blood. The patient was subsequently started on ibrutinib.
On admission to the hospital, an additional blood draw revealed a WBC count of 206,800 cells per mm 3 , plasma creatinine concentration of 5.5 mg per dL, potassium concentration of 6.9 mmol per L, uric acid concentration of 14.0 mg per dL, phosphorus concentration of 5.1 mg per dL (reference range, 2.5 to 4.5 mg/dL), calcium concentration of 8.1 mg per dL, and lactate dehydrogenase (LDH) concentration of 751 U per L (reference range, 135 to 225 U/L) ( Table 1) . Based on these findings, we diagnosed the patient with tumor lysis syndrome and acute on chronic kidney injury. Treatment with rasburicase, intravenous fluids, calcium gluconate, and insulin was prescribed. We also detected atrial fibrillation without rapid ventricular response and treated it with metoprolol. Blood specimens for measuring uric acid concentrations after rasburicase treatment were transported on ice and analyzed as soon as they arrived at the laboratory because rasburicase Abbreviations WBC, white blood cell; ANCA, antineutrophil cytoplasm antibody; LDH, lactate dehydrogenase; ABG, arterial blood gas continues to catalyze the enzymatic oxidation of uric acid to allantoin even within the blood tubes. Transporting specimens at room temperature or delays in uric acid analysis will result in falsely low concentrations.
Potassium concentrations in plasma specimens from our patient subsequently rose to a maximum of 9.2 mmol per L within 12 hours of hospital admission; creatinine concentrations were 3.4 mg per dL; uric acid, 9.9 mg per dL; phosphorus, 4.4 mg per dL; and calcium, 7.1 mg per dL. We observed no significant changes in WBC count or LDH concentrations during this period.
Because the WBC count of the patient was greater than 100,000 cells per mm 3 , we suspected reverse pseudohyperkalemia; also, whole blood potassium revealed a concentration of 7.7 mmol per L. Due to the high potassium concentrations and low urine output, hemodialysis was performed on the patient on day 2 of his hospitalization; whole blood potassium levels had decreased to 5.7 mmol per L. However, on day 3 of hospitalization, the potassium concentrations in whole blood specimens from the patient continued to rise. On day 4 of hospitalization, his whole blood potassium concentrations rose to greater than 9 mmol per L. Because we suspected continuing tumor lysis, we resumed hemodialysis, closely monitoring whole blood potassium concentrations. The prolonged hyperkalemia, despite hemodialysis and cessation of ibrutinib, prompted further investigation. On the recommendation of the laboratory director, a serum specimen was drawn from the patient to determine potassium concentration. The serum potassium concentration (3.1 mmol/L) revealed that the patient had hypokalemia. Potassium concentrations were also immediately measured on a blood gas analyzer, the ABL 800 FLEX (Radiometer America, CA, USA), from a whole blood specimen in a balanced lithium heparin syringe; the results were confirmed to indicate hypokalemia. The potassium concentration for the patient subsequently was corrected by using serum specimens ( Table 2) . Throughout the entire hospitalization of the patient, his WBC count was greater than 100,000 cells per mm 3 .
Discussion
The regulation of extracellular potassium concentration is critical for life. Fluctuations in extracellular potassium, particularly hyperkalemia, affect cell membrane potential and can trigger fatal arrhythmias. 1 Hyperkalemia can occur in tumor lysis syndrome along with hyperuricemia, hyperphosphatemia, and hypocalcemia. This sequence of events can also trigger acute kidney injury, 2 as we observed in this patient.
In the core laboratory of our institution, potassium is measured using an indirect ion-selective electrochemical method that selectively allow potassium ions to interact with the electrode. A commonly used type of ion-selective membrane for potassium is a polyvinyl chloride membrane incorporated with valinomycin. 3 However, blood-gas analyzers with direct ion-selective electrodes are available in patient wards for measuring whole blood potassium concentrations. Serum, plasma, and whole blood are generally acceptable specimen types for measurement of potassium concentrations.
A number of preanalytical factors can affect potassium concentrations in specimens. Mechanical trauma, such as tourniquet time greater than 1 minute, was found to increase the odds of hemolysis and to spuriously elevate potassium concentrations. 4 Other mechanical stresses, such as traumatic venipuncture, vigorous mixing, or even excessive fist clenching have been identified as causes of spuriously elevated potassium concentrations. 1, 5 Decrease in ambient temperature and a delay of more than 2 hours in centrifugation has led to "seasonal pseudohyperkalemia" in some regions where specimens must be transported over long distances 6 due to inhibition of the sodium-potassium pump that results in extracellular potassium leakage. 5 Familial pseudohyperkalemia is a rare, autosomal dominant cause of pseudohyperkalemia due to leakage of potassium across the red blood cell membrane when the specimen is stored at room temperature. 7, 8 Some authors have defined any spurious elevation of potassium as pseudohyperkalemia. However, in a strict sense, pseudohyperkalemia is an in vitro phenomenon in which serum potassium concentrations are elevated compared with plasma potassium concentrations. This phenomenon usually occurs in association with thrombocytosis. Serum and plasma are distinguished by the presence or absence of clotting factors, and pseudohyperkalemia is believed to be caused by potassium release from activated platelets during clot formation in serum. 9 For this reason, measurement of heparinized whole blood and plasma yield results that are representative of the true physiologic state of the patient, whereas serum gives falsely elevated results.
Reverse pseudohyperkalemia, in contrast, is an in vitro phenomenon in which plasma potassium concentrations rise higher than serum potassium concentrations, usually due to significant leukocytosis. 10 A longitudinal study by Katkish et al 11 demonstrated that an increased WBC count increased the possibility of spuriously elevated potassium concentrations. The leukemic leukocytes are believed to be more fragile than normal leukocytes, leading to in vitro lysis during centrifugation of plasma specimens and elevating potassium concentrations. 1, 12 In another case report of pseudohyperkalemia, LDH was used as a surrogate for leukemic cell lysis; the results demonstrated increased LDH and potassium concentrations in plasma, whereas no such increases were observed in serum or whole blood. 13 In serum specimens, the formation of a fibrin clot is hypothesized to entrap and stabilize tumor cells during centrifugation. The presence of a "buffy coat" above the plasma gel, which is not observable on the serum gel, has been described. 12, 14 A similar finding was discovered in specimens from our patient (Image 1).
Whole blood has been described as an alternative specimen in cases of reverse pseudohyperkalemia. 12 Despite that The patient from whom the specimens were drawn was a 66-year-old Caucasian man.
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Image 1
Buffy coat is present in spun plasma specimen (right) but absent in spun serum specimen (left).
assertion, we hypothesized that whole blood specimens from our patient, which were transported to the laboratory by pneumatic tubes, may have undergone in-vitro lysis of tumor cells, especially in patients with tumor lysis syndrome. Immediate testing of whole blood with blood gas analyzers at the bedside demonstrated significantly lower potassium concentrations, compared with pneumatic tube-delivered whole blood specimens that were tested in the core laboratory ( : falsely elevated whole blood potassium concentrations were observed when specimens were delivered via pneumatic tubes, whereas the potassium concentrations in serum specimens delivered via the same method remained stable.
Other possible contributing mechanisms for reverse pseudohyperkalemia include heparin-induced cellmembrane damage and Na/K-ATPase activity on leukemic cells. In a case report, Meng and Krahn 13 showed that plasma and whole blood collected via lithium heparin tubes had elevated potassium concentrations compared with serum.
Conclusion
This particular case study highlights the difficulty in distinguishing between true hyperkalemia in a setting of possible tumor lysis syndrome and reverse pseudohyperkalemia, especially when both entities may occur simultaneously. Although the initial laboratory results for specimens from the patient were consistent with tumor lysis syndrome according to the Cairo-Bishop criteria, 18 tumor lysis syndrome subsequent to ibrutinib therapy in mantle-cell lymphoma has only been reported in several cases. 19 However, tumor lysis syndrome constitutes a hematologic emergency that requires immediate treatment. In our patient, reverse pseudohyperkalemia complicated the clinical picture and explains why the patient appeared to have persistent hyperkalemia. A high index of suspicion and correlation with other clinical and laboratory findings is especially crucial in these cases because masked hypokalemia may occur. 5 Also, measurements of potassium concentrations using different specimen types, particularly serum, and transportation methods (pneumatic tube, hand carried, or at the point of care) may be helpful in detecting such occurrences. Based on the current literature and our case findings, serum is arguably the optimal specimen type in cases of suspected reverse pseudohyperkalemia. LM
